FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3094711031> ?p ?o ?g. }

• W3094711031 endingPage "48" @default.
• W3094711031 startingPage "48" @default.
• W3094711031 abstract "Introduction Peripheral neuropathy (PNP) remains one of the most common adverse events during multiple myeloma (MM) treatment. The immunomodulatory agent thalidomide and proteasome inhibitor bortezomib are particularly prone to induce PNP (Dimopoulos MA et al., Leukemia., 2010). Both agents are part of standard treatment regimens for newly diagnosed transplant-eligible MM patients. PNP varies from mild symptoms to severe disability, depending on timely dose reduction or discontinuation of treatment. Currently, incidence or severity of PNP cannot be predicted. Therefore, it is of utmost importance to monitor incidence of PNP in different treatment combinations, and in order to identify risk factors for developing PNP. Aims To investigate the incidence of PNP in patients treated in the Cassiopeia trial, to evaluate the role of CD38 antibody (daratumumab) treatment in development of PNP, and to identify risk factors for the development of PNP. Methods We retrospectively analysed incidence of PNP grade 2 to 4, scored according to common terminology criteria for adverse events version 4 (CTCAE) in the Cassiopeia study, a phase III trial conducted by IFM/HOVON, investigating the efficacy of adding daratumumab to bortezomib, thalidomide and dexamethasone (VTD). 1074 newly diagnosed MM patients were randomised. Patients received 4 induction cycles and 2 post transplantation consolidation cycles of 28 days each. Cycles included subcutaneous bortezomib (1.3 mg/m2 days 1,4,8,11), oral thalidomide (100 mg daily), dexamethasone (20-40 mg) and daratumumab intravenously (16 mg/kg and weekly during induction cycles 1 and 2 and once every two weeks during induction cycles 3,4 and consolidation). This trial was registered as ClinicalTrials.gov NCT02541383 and was supported by the French IFM and Dutch HOVON groups (Moreau et al., Lancet, 2019). Multivariate analysis was performed including sex, age, arm, body mass index (BMI), cytogenetics, ISS stage, country, diabetes mellitus (DM), creatinine clearance, liver function, ECOG, baseline PNP and disease characteristics. Results Baseline characteristics in dara-VTD and VTD arms were similar. Overall, 380/1074 (35%) patients developed grade ≥2 PNP and 102/1074 (9%) patients developed grade ≥3 PNP. Multivariate analysis indicated that the cumulative incidence of PNP grade ≥2 was significantly lower in the dara-VTD arm (33%) when compared to the VTD arm (38%) (hazard ratio (HR)=0.73, 95% confidence interval (CI) 0.59-0.91, P=0.004). Furthermore, risk factors associated with a higher cumulative incidence of PNP grade ≥2 included older age (HR=1.03; P=0.020), grade 1 PNP at baseline (HR= 2.75; P= 0.002) and higher BMI (HR=1.46, P=0.003 for BMI 25-30 to HR=2.02, P=0.004 for BMI &gt; 35). Progression free survival (PFS) from the end of induction was similar (86% vs 80% at 2 years, HR = 0.74, 95% CI 0.41-1.33, P=0.32) for patients developing grade ≥2 PNP during induction (179 pts, 17%). An unexpected finding was the difference in cumulative incidence between countries participating in this trial: in the Netherlands 68/141 (49%) of patients developed grade ≥2 PNP, while in France this was 280/846 (33%) and in Belgium 31/87 (36%) (p&lt;0.001). The protocol of the Cassiopeia trial included instructions of discontinuation and dose modification, when PNP grade ≥2 was observed. However, in a subset of patients reaching PNP grade ≥ 2 the (temporary) discontinuation or adjustment of dose as described in the treatment protocol had not been applied (respectively in 148/352 (42%) with PNP ≥ 2 and in 39/97 (40%) with PNP ≥3). Conclusions Despite bortezomib being administered subcutaneously and clear instructions on discontinuation and dose modification, we observed a clinically relevant incidence of grade ≥2 PNP (35%) and grade ≥3 PNP (9%) in patients treated in the Cassiopeia trial. Patients in the dara-VTD arm showed less grade ≥2 PNP, suggesting a possible positive effect of daratumumab. Risk factors for the development of grade ≥2 PNP included older age, PNP at baseline and BMI &gt; 25. Differences in incidence between countries were observed, however no clear explanation was found. Furthermore, standard measures for grading PNP, such as CTCAE criteria, are subject to interpretation bias of both the patient and the treating physician. Continuous screening and correct grading of PNP and strict compliance with guidelines is warranted. Disclosures Moreau: Amgen: Consultancy, Honoraria; Celgene/Bristol-Myers Squibb: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; Abbvie: Consultancy, Honoraria; Takeda: Honoraria; Sanofi: Consultancy, Honoraria; Novartis: Honoraria. Vermeulen:Janssen: Current Employment, Current equity holder in publicly-traded company. Broyl:Janssen, Celgene, Takeda, Amgen: Honoraria. Sonneveld:Sanofi: Consultancy; Takeda: Consultancy, Honoraria, Research Funding; Bristol-Myers Squibb: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria, Research Funding; Karyopharm: Consultancy, Honoraria, Research Funding; Skyline Dx: Honoraria, Research Funding; Amgen: Consultancy, Honoraria, Research Funding." @default.
• W3094711031 created "2020-11-09" @default.
• W3094711031 creator A5002972322 @default.
• W3094711031 creator A5006382528 @default.
• W3094711031 creator A5012101669 @default.
• W3094711031 creator A5014723513 @default.
• W3094711031 creator A5048903346 @default.
• W3094711031 creator A5069921733 @default.
• W3094711031 creator A5080712446 @default.
• W3094711031 creator A5086554449 @default.
• W3094711031 creator A5089637265 @default.
• W3094711031 date "2020-11-05" @default.
• W3094711031 modified "2023-10-14" @default.
• W3094711031 title "Peripheral Neuropathy in the Cassiopeia Study" @default.
• W3094711031 doi "https://doi.org/10.1182/blood-2020-137400" @default.
• W3094711031 hasPublicationYear "2020" @default.
• W3094711031 type Work @default.
• W3094711031 sameAs 3094711031 @default.
• W3094711031 citedByCount "1" @default.
• W3094711031 countsByYear W30947110312021 @default.
• W3094711031 crossrefType "journal-article" @default.
• W3094711031 hasAuthorship W3094711031A5002972322 @default.
• W3094711031 hasAuthorship W3094711031A5006382528 @default.
• W3094711031 hasAuthorship W3094711031A5012101669 @default.
• W3094711031 hasAuthorship W3094711031A5014723513 @default.
• W3094711031 hasAuthorship W3094711031A5048903346 @default.
• W3094711031 hasAuthorship W3094711031A5069921733 @default.
• W3094711031 hasAuthorship W3094711031A5080712446 @default.
• W3094711031 hasAuthorship W3094711031A5086554449 @default.
• W3094711031 hasAuthorship W3094711031A5089637265 @default.
• W3094711031 hasBestOaLocation W30947110311 @default.
• W3094711031 hasConcept C120665830 @default.
• W3094711031 hasConcept C121332964 @default.
• W3094711031 hasConcept C126322002 @default.
• W3094711031 hasConcept C141071460 @default.
• W3094711031 hasConcept C197934379 @default.
• W3094711031 hasConcept C2776364478 @default.
• W3094711031 hasConcept C2777478702 @default.
• W3094711031 hasConcept C2777793932 @default.
• W3094711031 hasConcept C2778715236 @default.
• W3094711031 hasConcept C2779609412 @default.
• W3094711031 hasConcept C2781119759 @default.
• W3094711031 hasConcept C61511704 @default.
• W3094711031 hasConcept C71924100 @default.
• W3094711031 hasConcept C90924648 @default.
• W3094711031 hasConceptScore W3094711031C120665830 @default.
• W3094711031 hasConceptScore W3094711031C121332964 @default.
• W3094711031 hasConceptScore W3094711031C126322002 @default.
• W3094711031 hasConceptScore W3094711031C141071460 @default.
• W3094711031 hasConceptScore W3094711031C197934379 @default.
• W3094711031 hasConceptScore W3094711031C2776364478 @default.
• W3094711031 hasConceptScore W3094711031C2777478702 @default.
• W3094711031 hasConceptScore W3094711031C2777793932 @default.
• W3094711031 hasConceptScore W3094711031C2778715236 @default.
• W3094711031 hasConceptScore W3094711031C2779609412 @default.
• W3094711031 hasConceptScore W3094711031C2781119759 @default.
• W3094711031 hasConceptScore W3094711031C61511704 @default.
• W3094711031 hasConceptScore W3094711031C71924100 @default.
• W3094711031 hasConceptScore W3094711031C90924648 @default.
• W3094711031 hasIssue "Supplement 1" @default.
• W3094711031 hasLocation W30947110311 @default.
• W3094711031 hasOpenAccess W3094711031 @default.
• W3094711031 hasPrimaryLocation W30947110311 @default.
• W3094711031 hasRelatedWork W2013902170 @default.
• W3094711031 hasRelatedWork W2036787255 @default.
• W3094711031 hasRelatedWork W2072770520 @default.
• W3094711031 hasRelatedWork W2090603150 @default.
• W3094711031 hasRelatedWork W2364188423 @default.
• W3094711031 hasRelatedWork W2379764382 @default.
• W3094711031 hasRelatedWork W2403269090 @default.
• W3094711031 hasRelatedWork W2411672121 @default.
• W3094711031 hasRelatedWork W2950984087 @default.
• W3094711031 hasRelatedWork W2944892461 @default.
• W3094711031 hasVolume "136" @default.
• W3094711031 isParatext "false" @default.
• W3094711031 isRetracted "false" @default.
• W3094711031 magId "3094711031" @default.
• W3094711031 workType "article" @default.